Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets

Joyce S. F. D. Almeida, Fernanda D. Botelho, Felipe R. de Souza, Marcelo C. dos Santos, Arlan da Silva Goncalves, Rodrigo L. B. Rodrigues, Monique Cardozo, Daniel A. S. Kitagawa, Leandro A. Vieira, Raphael S. F. Silva, Samir F. A. Cavalcante, Leonardo da C. Bastos, Mariana de O. T. Nogueira, Priscila I. R. de Santana, Juliana de O. C. Brum, Eugenie Nepovimova, Kamil Kuca, Steven R. LaPlante, Erick B. F. Galante, and Tanos C. C. Franca

Key Laboratory of Molecular Modeling Applied to Chemical and Biological Defense (LMCBD), Military Institute of Engineering, Rio de Janeiro, Brazil; Department of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro/RJ, Brazil; Department of Chemistry, Federal Institute of Espirito Santo - Unit Vila Velha, Vila Velha/ES, Brazil; PPGQUI (Graduate Program in Chemistry), Federal University of Espirito Santo, Vitoria/ES, Brazil; Department of Chemical Engineering, Instituto Militar de Engenharia, Rio de Janeiro/RJ, Brazil; Institute of Chemical, Biological, Radiological and Nuclear Defense (IDQBRN), Brazilian Army Technological Center (CTEx), Rio de Janeiro/RJ, Brazil; Coordination of Chemistry, Federal Institute of Education Science and Technology of Rio de Janeiro, Rio de Janeiro/RJ, Brazil; Faculty of Science, Department of Chemistry, University of Hradec Králové, Hradec Králové, Czech Republic; INRS, Centre Armand-Frappier Sante Biotechnologie 531, Boulevard des Prairies, Laval, QC, Canada.

Communicated by Ramaswamy H. Sarma

ABSTRACT

The acute respiratory syndrome caused by the SARS-CoV-2, known as COVID-19, has been ruthless tormenting the world population for more than six months. However, so far no effective drug or vaccine against this plague have emerged yet, despite the huge effort in course by researchers and pharmaceutical companies worldwide. Willing to contribute with this fight to defeat COVID-19, we performed a virtual screening study on a library containing Food and Drug Administration (FDA) approved drugs, in a search for molecules capable of hitting three main molecular targets of SARS-CoV-2 currently available in the Protein Data Bank (PDB). Our results were refined with further molecular dynamics (MD) simulations and MM-PBSA calculations and pointed to 7 multi-target hits which we propose here for experimental evaluation and repurposing as potential drugs against COVID-19. Additional rounds of docking, MD simulations and MM-PBSA calculations with remdesivir suggested that this compound can also work as a multi-target drug against SARS-CoV-2.

INTRODUCTION

According to the literature SARS-CoV-2 belongs to the coronavirus family which has been around and causing pandemics for a while. However, this time the infection caused, called COVID-19, is a bit worse and capable of collapsing the lungs very quickly, killing the patient if no respiratory support is provided, being declared a worldwide pandemic in 11 March 2020 by the World Health Organization (WHO). In most countries the shortage of enough respirators, as well as, specialized personal to operate them, aroused a big fear of collapsing in the health systems. Therefore, social distancing and/or lockdown of the entire population was the most immediate response to this situation in order of smoothing the progress curve of the disease, and saving the Governments some time for preparing their health systems for facing properly this pandemic (Bedford et al., 2020; Cucinotta & Vanelli, 2020; Ortiz-Prado et al. 2020; Velavan & Meyer, 2020).

However, improving the health infrastructure is not enough and the situation will be totally under control only after the naturally achieving of herd immunity by the population, the development of a vaccine, or emergence of a drug capable of avoiding the respiratory complications of COVID-19 (Fierabracci et al., 2020; Gates, 2020). As the first two options can take months, maybe more than a year, the most immediate solution to beat COVID-19 is the search for new drugs based on the repurposing approach (Pushpakom et al., 2019). On this sense we performed a comprehensive virtual screening (VS) study on a library comprising FDA approved drugs in a search for molecules capable of hitting the three main molecular targets of SARS-CoV-2 currently available in the protein data bank (PDB) (https://www.rcsb.org/) (Berman et al., 2000a).

In order to select which proteins would be studied in terms of their interactions with small molecules, we analyzed the role that different proteins play in SARS-CoV-2 mechanisms of replication or cell entrance, and the availability and quality of their

CONTACT Tanos C. C. Franca; tanos@ime.eb.br Laboratory of Molecular Modeling Applied to Chemical and Biological Defense (LMCBD), Military Institute of Engineering, Rio de Janeiro, Brazil.

Universidade Castelo Branco (UCB), School of Pharmacy, Rio de Janeiro/RJ, Brazil.

Supplemental data for this article can be accessed online at https://doi.org/10.1080/07391102.2020.1869096.

© 2020 Informa UK Limited, trading as Taylor & Francis Group
three-dimensional structures in the PDB (https://www.rcsb.org/) (Berman et al., 2000a). All selected proteins are part of the viral machinery responsible for the replication and transcription of SARS-CoV-2 RNA genome or play important roles in the viral mechanisms of entrance inside human cells. Main protease (Mpro) is responsible for proteolysis of polyproteins 1a and 1ab, generating smaller proteins that are necessary for the virus replication (Jin et al., 2020; Rathnayake et al., 2020). Spyke protein is a homotrimer located in the external surface of the virus and contains the receptor-binding domain (RBD), which directly binds to the peptidase domain of the angiotensin-converting enzyme 2 (ACE2), and consequently promotes the entrance of the virus inside the cell (Cao et al., 2020; Yan et al., 2020). Finally, papain-like protease (PLpro) is responsible for processing of polyproteins 1a and 1ab, generating smaller proteins that are necessary for the virus replication (Jin et al., 2020; Rathnayake et al., 2020). SPyke protein is a homotrimer located in the external surface of the virus and contains the receptor-binding domain (RBD), which directly binds to the peptidase domain of the angiotensin-converting enzyme 2 (ACE2), and consequently promotes the entrance of the virus inside the cell (Cao et al., 2020; Yan et al., 2020). Finally, papain-like protease (PLpro) is responsible for processing of polyproteins 1a and 1ab, generating smaller proteins that are necessary for the virus replication (Jin et al., 2020; Rathnayake et al., 2020).

Our search screened 1930 compounds contained in the FDA-approved drugs data set available at the Cheminformatic tools and Databases server (Chemoinfo (https://chemoinfo.ipmc.cnrs.fr/)) (Douguet, 2010, 2018) against the targets cited above, and the 50 best molecules were selected for further docking studies using Molegro Virtual Docker (MVD) 6.0 (Thomsen & Christensen, 2006), in order to confirm their potential for drug repurposing against COVID-19. The 7 drugs that showed potential to bind the three protein targets selected in this study were submitted to molecular dynamics (MD) simulations and MM-PBSA calculations in order to corroborate the docking results. We also performed the same theoretical studies for remdesivir in complex with each target protein, since this drug has been reported in literature as presenting promising in silico and experimental results for the treatment of patients with COVID-19 (Grein et al., 2020; Hendaus, 2020; Naik et al., 2020; Wang et al., 2020).

### Methodology

#### Virtual screening studies

#### Targets and search space

The molecular targets selected from the PDB (Berman et al., 2000b) and their respective binding pockets chosen to run

| PDB Code | Protein | Abbreviation used in this work | Binding pocket | Residues | References |
|----------|---------|-------------------------------|----------------|---------|------------|
| 6XMK     | SARS-CoV-2 main protease in complex with the inhibitor 7 (IC50 = 0.45 μM) | SC2Mpro | Active site | Gly143, Cys145, His163, His164, Glu166, Gin189, Thr190 | Rathnayake et al., 2020 |
| 7CMD     | Papain-like protease of SARS-CoV-2 in complex with the inhibitor GRL0617 (IC50 = 2.2 µM) | SC2PLpro | Active site | Cys111, Gly163, Asp164, Tyr264, Tyr268, Gly271, His272, Asp286 | Gao et al., 2020 |
| 7JZU     | SARS-CoV-2 spike in complex with the peptide LCB1 (IC50 = 23.5 pM) | SC2Spyke | RBD | Lys417, Gly446, Tyr449, Tyr453, Leu455, Phe456, Ala475, Phe486, Asn487, Tyr489, Gin493, Gly496, Gln498, Thr500, Asn501, Gly502, Tyr505 | Gao et al., 2020 |

#### Libraries

As mentioned above we used the FDA-approved drugs data set (called here FDA-library) available at Chemolinfo server (https://cheminfo.ipmc.cnrs.fr/) that provided 1930 FDA-approved drugs ready for docking (Douguet, 2010, 2018). Those molecules were evaluated regarding their interactions with each of the protein targets listed in Table 1.

#### Receptor-based virtual screening (RBVS)

A Receptor-based Virtual Screening (RBVS) was carried out for each target protein separately using the ChemoInfo VS tool, which employs the docking algorithm Protein-Ligand ANT System (PLANTS) (Korb et al., 2009). For each target protein, the respective .pdb file and coordinates of the center of the binding site, as defined in Table 2, were given as inputs. After evaluation of the FDA-library, the Chemolinfo VS tool returned the results consisting on a list of the molecules ranked by the PLANTS (Korb et al., 2009) scoring function. The top results correspond to molecules that stablished the most favorable interactions with the target.

For each target, the best 50 results returned by the Chemolinfo VS tool were retrieved and these results were filtered in order to remove drugs that mainly act in the central and/or peripheral nervous system, renal system and/or cardiovascular system, because these effects would make it
impossible to use those types of drugs in patients infected with COVID-19. After the filtering, we looked for drugs that showed potential to interact with more than one target protein and, therefore, triggering a synergistic effect, enhancing their potential to stop or slow down the SARS-CoV-2 action inside the human body. The drugs were then ranked in decreasing order of the number of protein targets that they interacted favorably with and, the ones showing favorable interactions with the three targets, were submitted to MVD® and rounds of MD simulation and MM-PBSA calculations. A flowchart summarizing the VS procedure used in this study is illustrated in Figure 1.

**Docking studies**

The drugs that showed favorable interactions with all three targets selected in this work were submitted to MVD®, using the same protocol validated before (Botelho et al., 2020), in order to re-evaluate the protein-ligand interactions using the Moldock Score, a docking algorithm more accurate than PLANTS (Korb et al., 2009). For this task their 3D structures were constructed in the Spartan 08 software (Hehre et al., 2006), using the semi-empirical method Parametric Method 3 (PM3) (Stewart, 2004) for geometry optimization, and the Natural Population Analysis (NPA) (Reed et al., 1985) method for atomic charges calculations.

For each protein-ligand complex, 10 runs were carried out in the search spaces defined in Table 2, with 30 poses returned for each run. Those poses were analyzed regarding their MolDock Score and the residues they formed hydrogen bonds (H-bonds) with. After, the best pose of each drug in each target was selected to be submitted to MD simulations and MM-PBSA calculations. The complexes remdesivir/targets were also generated with MVD®, following the same protocol described above and the best poses also selected for the further MD simulations and MM-PBSA calculations. The interaction energies of the ligands found inside the crystallographic structures listed in Table 1 were also determined using MVD® for reference purposes.

**Molecular dynamics simulations**

The molecular dynamics (MD) simulations studies were performed applying the bonded and non-bonded parameters for the all-atom force field OPLS-AA (Kaminski et al., 2001). The three-dimensional coordinates and topologies of the targets listed in Table 1 were generated by the pdb2gmx software, which is part of the GROMACS 5.1.4 package (Berendsen et al., 1995; Hess et al., 2008; Pronk et al., 2013; Van Der Spoel et al., 2005), used in this work to perform all MD simulations. Since the OPLS-AA force field (Kaminski et al., 2001) has no parameters for the ligands studied, the AcPyPe software (Sousa Da Silva & Vranken, 2012), was used to generate topology and coordinates files of all ligands submitted to MD simulations. The Restrained Electrostatic Potential (RESP) method (Bayly et al., 1993; Cornell et al., 1993; Ribeiro et al., 2008; Wang et al., 2000) parameterized to reproduce the method Hartree-Fock and the basis set 6-31G* (Jakalian et al., 2002), was applied to calculate the atomic charges.

The target proteins complexed with the selected ligands were confined inside boxes under periodic boundary conditions (Martinez et al., 2007) where the effect of the solvent was reproduced by the water model TIP4P (Harrach & Drossel, 2014; Jorgensen et al., 1983; Mark & Nilsson, 2001). For each target protein, the box format and size were selected seeking optimization of simulation time and absence of undesired artifacts. The boxes volumes and approximate numbers of water molecules of each system are listed in Table 3. All systems were submitted to two minimization steps using the steepest descent algorithm with the convergence criterion of 100.00 kJ mol⁻¹ nm⁻¹. The first step with position restrained (PR) and the second without PR. The equilibration of pressure and temperature was achieved through 100 ps of simulation using the canonical ensemble (NVT) (Bosko et al., 2005), keeping the number of particles, volume and temperature constant. This was followed by 100 ps of simulation with an isothermal-isobaric ensemble (NPT) (Bosko et al., 2005), keeping the number of particles, pressure, and temperature constant. After the equilibration step, all systems were submitted to a production step of 50 ns. All MD simulations were performed at 310 K and 1 bar, using 2 fs of integration time with the lists of pairs being updated at every 5 steps. The cut-off for Lennard Jones and Coulomb interactions were between 0 and 1.2 nm. The leap-

---

**Table 3. Boxes volumes, formats and numbers of water molecules of each system.**

| Protein name | Box volume (nm³) and format | Number of TIP4P water molecules |
|--------------|-----------------------------|---------------------------------|
| SC2Mpro      | 849.6, dodecahedron         | 26,100                          |
| SC2SPyke     | 567.87, dodecahedron        | 17,671                          |
| SC2PPLpro    | 1204.7, dodecahedron        | 37,700                          |
frog algorithm was used in the production step with the Nose-Hoover thermostat (Evans & Holian, 1985) (τ = 0.5 ps) at 310 K and the Parrinello-Rahman barostat (Parrinello & Rahman, 1981) (τ = 2.0 ps) at 1 bar. All Arg and Lys residues were assigned with positive charges and all Glu and Asp residues were assigned with negative charges. The Visual Molecular Dynamics (VMD) (Humphrey et al., 1996) software was used to visualize the simulation trajectories, and the Grace program (Turner, 2005) was used to build graphs of energy and root mean square deviation (RMSD). Additionally, the same procedure described above was used to run 100 ns of MD simulations with the three crystallographic complexes listed in Table 3, in order to validate our MD simulation protocol.

**MM-PBSA calculations**

MM-PBSA calculations of the binding free energies of each ligand after the MD simulations were carried out in order to support the former results. Through this method it is possible to predict the binding free energy of the ligands considering the vacuum potential energy, which includes both bonded and nonbonded interactions, as well as the free energy of solvation, which considers both polar and nonpolar terms (Kumari et al., 2014). After MD simulations, the ligands were submitted to the g_mmpbsa tool (Kumari et al., 2014) of GROMACS 5.1.4 package (Berendsen et al., 1995; Hess et al., 2008; Pronk et al., 2013; Van Der Spoel et al., 2005) and their complexes with each target had their binding free energies calculated following the same protocol used before (da Silva et al., 2019; de Almeida et al., 2019).

### Results and discussion

#### Receptor-based virtual screening (RBVS)

The search for potential multitarget drugs returned the 7 drugs listed in Table 4, which have the potential of interacting with all targets listed in Table 1, suggesting that further

| Drug Structure | Drug Structure |
|----------------|----------------|
| Remdesivir     | Elbasvir       |
| Cobicistat     | Nystatin       |
| Ritonavir      | Amphotericin B |
| Deferoxamine   | Itraconazole   |

**Table 4. Drugs selected through RBVS plus remdesivir.**

| Drug | Structure |
|------|-----------|
| Remdesivir | ![Remdesivir](image) |
| Elbasvir   | ![Elbasvir](image)  |
| Cobicistat | ![Cobicistat](image) |
| Nystatin   | ![Nystatin](image) |
| Ritonavir  | ![Ritonavir](image) |
| Amphotericin B | ![Amphotericin B](image) |
| Itraconazole | ![Itraconazole](image) |
repurposing studies of those drugs might lead to the discovery of an existing drug with potential to treat COVID-19. The structure of remdesivir is also shown in Table 4.

Some of the drugs presented in Table 4 have very similar structures that justify their similar results. Cobicistat and ritonavir, two antiviral drugs, share several common characteristics as well as nystatin and amphotericin B, which are also very similar to each other. Although having different structures, deferoxamine, itraconazole and elbasvir also showed potential to form stable complexes with all targets. Despite the structural differences, all drugs in Table 4 share the common feature of having several highly electronegative atoms linked to hydrogen atoms, i.e. spots where H-bonds can be formed, which probably contributed to their ability to form stable complexes with multiple proteins.

As mentioned above the 8 drugs presented in Table 4 were submitted to more docking calculations, with each molecular target chosen in this work, using MVD®, so multiple poses per drug per protein could be analyzed regarding their stability.

**Docking studies**

The results of docking calculations using MVD® shown in Figures 2–5, Table S1 and Figures S1–S25, confirmed the RBVS results, showing that the best poses of all 7 selected drugs are capable of binding to the targets, presenting large negative values of interacting energy (most below −100.00 kcal mol⁻¹) comparable with the results for the reference ligands inside SC2Mpro and SC2Plpro. In the case SC2Spyke the interaction energy of the reference ligand is not comparable to our ligands once the peptide LCB1 is a much larger ligand. This peptide is capable of establishing many more interactions with the RDB domain of SC2Spyke (see Figure S25), reflecting in the much more negative binding energy value shown in Figure 5. Our ligands, however, presented binding energies with SC2Spyke similar to the other targets which is enough to qualify them as potential good binders to this protein. It was also observed that remdesivir showed similar energy values with all targets. This suggests that it can also qualify as a multi-target drug against SARS-CoV-2. Among the residues observed in interactions with the best poses of each ligand, it’s possible to see in the 3D plots of Figures 2–4 and the 2D plots of Figures S1–S24 that most of the residues listed in Table 1 present some kind of interaction with the ligands and, also, that at least one residue of the respective binding site forms H-Bond with the ligand. This confirms that the selected drugs are capable of binding in the binding sites pointed in Table 1 and, therefore, have potential to inhibit the selected targets.
Elbasvir was the best binder to all targets according to the docking results, with energy values always below $-150 \text{ Kcal/mol}$, while deferoxamine presented the worse (highest) energy values with all targets except SC2Mpro, where it was the second worse (Table S1). The other 5 ligands presented oscillating results among the targets, ranking well with some and not so well with others.

The selection of the best pose of each drug in each target resulted in 24 systems ligand/target that were submitted to additional rounds of MD simulations and MM-PBSA calculations.

**Molecular dynamics simulations**

In order to corroborate the docking results, 50 ns of MD simulations were performed with the 24 systems described above (one pose per drug of Table 4 in complex with each protein described in Table 1), plus the three crystallographic complexes listed in Table 3, following the protocol described in the methodology section.

Plots of total and average energy of the crystallographic complexes (Figure S26) show that the systems achieve stability since the beginning of the simulation and allowed reducing the simulated time to 50 ns in order to save computing resources.

Figures S27–S29 and the RMSD of each protein/ligand complex (Figure 6), confirm the stability of the systems during all simulated time. It’s possible to see in those figures that the majority of the systems stabilized since the beginning of the MD simulations and that the RMSD of the ligands and proteins never oscillated over 0.7 nm. Deferoxamine and itraconazole were the ligands with worst behavior, showing larger RMSD oscillations with SC2Spyke (deferoxamine) and SC2Mpro (itraconazole). Elbasvir (shown in blue in Figure 6) behaved well when in complex with all three proteins, indicating the favorable interactions between this ligand and the SARS-CoV-2 targets. Nystatin, shown in pink, presented stable RMSD values specially when complexed with SC2PLpro and SC2Spyke. As for SC2Mpro, ritonavir (shown in purple) had a good behavior regarding RMSD values; pointing to the possibility of the administration of combined drugs for treating patients with COVID-19. Additionally, remdesivir, which has already shown promising clinical results for COVID-19 treatment (Grein et al., 2020; Hendaus, 2020; Naik et al., 2020; Wang et al., 2020), seems to form more stable complexes with SC2PLpro and SC2Spyke than with SC2Mpro, enlightening aspects of this drug action regarding SARS-CoV-2. The protein presenting worst behavior was SC2Mpro when complexed with amphotericin B.

The H-bonds formed between each protein and each drug during the MD simulations were also analyzed in order.
to verify if such interactions, predicted by docking studies (Figures 2–4), could also be observed during the MD simulations. The reference ligands were also analyzed in this aspect so the drugs could be compared to them in terms of H-bonds. Figures 7–9 show the H-bonds formed between each molecule and each protein. According to Figure 7, the
reference ligand to SC2M⁺pro tends to form H-bonds mainly with Glu166 (pink) and Gln189 (green). Amphotericin B, deferoxamine and remdesivir seems to be more promising ligands than the reference in terms of H-bonds, since they interacted with a larger variety of residues during the MD simulations. Regarding interactions with SC2PL⁺pro (Figure 8), elbasvir is not shown because it did not form H-bonds during most of the MD simulation, although this drug presented good docking and RMSD results. As for the other ligands, none seem to be able to form numerous H-bonds with this protein; indicating that there may have non-polar interactions contributing for the complexes stabilities. Remdesivir

Figure 6. RMSD plots of targets (left) and ligands (right) during 50 ns of MD simulations.
seems to be the only drug capable of forming more H-bonds with SC2PL\textsuperscript{pro} than the reference ligand. This results contributes to explain the already observed good clinical results of this drug. Considering SC2Spyke, Figure 9 shows that most drugs tend to form H-bonds mainly with Tyr449 (red) and Gln493 (blue), while the reference ligand formed H-bonds with multiple residues over the MD simulation time, mainly Lys417 (cyan), Asn487 (dark green), Gly502 (yellow), and
Tyr449 (red). This is not unexpected since the reference ligand is a peptide and has nearly 60 amino acids (Cao et al., 2020), so its size favors the formation of multiple interactions with SC2Spyke residues. Among the studied drugs, deferoxamine, nystatin and remdesivir are the ones that formed H-bonds with SC2Spyke residues during most of the MD simulation time, indicating that they tend to stay bound to this protein.

Figure 8. H-bonds formed between SC2PLpro and ligands. Elbasvir is not shown because it did not form significant H-bonds with this protein.
The results of the MM-PBSA calculations are shown in Figure 10. The negative binding energies predicted for all ligands (most below $-50 \text{ Kcal mol}^{-1}$) with all targets corroborated the docking and MD simulations results, confirming their stability and capacity of binding to these targets. Reference ligands of SC2Mpro and of SC2PLpro had similar results to the other drugs, confirming their potential to inhibit those
proteins. SC2Spyke reference ligand presented a significantly lower binding energy than all the other ligands, probably due to its high similarity with the SC2Spyke natural substrate (Cao et al., 2020) and consequent extremely low IC₅₀ value (Table 3). However, other drugs such as elbasvir, itraconazole, nystatin and ritonavir also had good MM-PBSA results for SC2Spyke. Comparing the drug performances for the three proteins, elbasvir and ritonavir are the drugs presenting best general results.

Conclusion

We performed a comprehensive theoretical study applying the methods of RBVS, docking, MD simulations and MM-PBSA calculations, that allowed the selection of 7 potential hits amongst 1930 drugs approved by the FDA (https://cheminfo.ipmc.cnrs.fr/MOLDB/index.php#ref1). Our 7 hits, together with remdesivir, showed capacity of effectively binding to the three main SARS-CoV2 targets SC2Mᵢᵣ, SC2PLᵢᵣ and SC2Spyke, qualifying as potential pre-approved multi-target drugs. These results suggest that these drugs, worth being immediately submitted to in vitro evaluation against SARS-CoV2. Also, the fact of being multi-target hits suggests that these compounds could have a synergistic effect if administered simultaneously against COVID-19. The most promising drugs for this, according to our results, are remdesivir, elbasvir and ritonavir.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

The authors wish to thank the financial support of the Brazilian agencies Conselho Nacional de Pesquisa (CNPq), grant number 308225/2018-0, Fundação de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), grant number E-02/202.961/2017, IFES—PRPQ, grant number 10/2019 (Productivity Researcher Program PPP), and FAPES, grant number 03/2020-2020-WMT5F. This work was also supported by the University of Hradec Králové (VT2019-2021). We also thanks the Federal University of Lavras (UFLA) for software facilities.
of the Brazilian Chemical Society, 19(7), 1433–1435. http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532008000700031&lng=en&nrm=iso&tlng=en. https://doi.org/10.1590/S0103-50532008000700031
Sousa Da Silva, A. W., & Vranken, W. F. (2012). ACPYPE - Antechamber python parser interface. BMC Research Notes, 5(1), 367. https://doi.org/10.1186/1756-0500-5-367
Stewart, J. J. P. (2004). Optimization of parameters for semiempirical methods IV: Extension of MNDO, AM1, and PM3 to more main group elements. Journal of Molecular Modeling, 10(2), 155–164. https://doi.org/10.1007/s00894-004-0183-z
Thomsen, R., & Christensen, M. H. (2006, June 1). MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry, 49(11), 3315–3321. https://doi.org/10.1021/jm051197e
Turner, P. J. (2005). XMGRACE, version 5.1.25. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology.
Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. C. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291
Velavan, T. P., & Meyer, C. G. (2020). The COVID-19 epidemic. Tropical Medicine & International Health: TM & Ih, 25(3), 278–280. https://doi.org/10.1111/tmi.13383
Wang, J., Cieplak, P., & Kollman, P. A. (2000). How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? Journal of Computational Chemistry, 21(12), 1049–1074. https://doi.org/10.1002/1096-987X(200009)21:12<1049::AID-JCC3.0.CO;2-F
Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., … Wang, C. (2020). Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236), 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020, March). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.), 367(6485), 1444–1448. https://doi.org/10.1126/science.abb2762